SCHEDULE 13G/A: FMR LLC and Abigail P. Johnson Disclose 14.0% Passive Stake in Dianthus Therapeutics Inc.
Beneficial Ownership Report
Investment giant FMR LLC and its CEO Abigail P. Johnson have reported a combined passive beneficial ownership of 14.0% in Dianthus Therapeutics Inc., holding 4,482,609 shares of common stock as of March 31, 2025.
Summary
- FMR LLC and Abigail P. Johnson collectively beneficially own 4,482,609 shares of Dianthus Therapeutics Inc. common stock.
- This ownership represents 14.0% of the total outstanding common stock of Dianthus Therapeutics Inc.
- The filing is an Amendment No. 1 to Schedule 13G, indicating a change from a previously filed statement.
- The ownership is classified as passive, meaning the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.
- FMR LLC holds sole voting power over 4,482,389 shares and sole dispositive power over 4,482,609 shares.
- Abigail P. Johnson holds sole dispositive power over 4,482,609 shares.
- The beneficial ownership is aggregated from various entities under FMR LLC, including FIAM LLC, Fidelity Institutional Asset Management Trust Company, Fidelity Management & Research Company LLC, and Fidelity Management Trust Company, with Fidelity Management & Research Company LLC noted as beneficially owning 5% or more individually.
Sentiment
Score: 6
Explanation: The filing is a factual disclosure of a significant passive ownership stake by a major institutional investor, FMR LLC, and its CEO. While the filing itself is neutral, a substantial stake from a reputable firm can be perceived as a positive signal for the issuer, Dianthus Therapeutics Inc.
Positives
- A major institutional investor, FMR LLC (Fidelity), has disclosed a significant 14.0% beneficial ownership stake in Dianthus Therapeutics Inc., which can be interpreted as a vote of confidence in the company's prospects.
- The stake is held by a reputable investment firm, suggesting a thorough due diligence process has been conducted.
Future Outlook
The document does not provide any forward-looking statements or guidance regarding Dianthus Therapeutics Inc.'s future outlook.
Industry Context
Dianthus Therapeutics Inc. operates in the biotechnology/pharmaceuticals sector. A significant institutional investment by a major firm like FMR LLC can signal confidence in the company's drug pipeline, research, or market potential within the industry.
Stakeholder Impact
- Shareholders: The disclosure of a significant institutional stake could positively influence investor sentiment and potentially the stock price, signaling confidence in the company.
- Management: Awareness of a large, passive institutional holder may subtly influence strategic decisions, although the filing explicitly states the stake is not for the purpose of changing or influencing control of the issuer.
Key Dates
| Date | Description |
|---|---|
| 01/03/2023 | Effective date of Power of Attorney for FMR LLC. |
| 01/26/2023 | Effective date of Power of Attorney for Abigail P. Johnson. |
| 03/31/2025 | Date of event which required the filing of this statement (ownership threshold met or changed). |
| 05/09/2025 | Date of filing and signature. |
Keywords
Dianthus Therapeutics Inc., FMR LLC, Abigail P. Johnson, Schedule 13G, beneficial ownership, common stock, institutional investment, passive stake, SEC filing, biotechnology, pharmaceuticals
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.